Drug Trial Radar · NCT07020988
A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
55
Actual
Start
Jun 12, 2025
Primary completion
Jan 6, 2026
Study completion Jan 21, 2026
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Jun 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and β1 frequency bands in the qEEG (quantitative electroencephalogram).
Conditions
- Healthy Participants
Interventions
Staccato AlprazolamDrug
Study participants will receive single dose of Staccato Alprazolam at pre-specified time points.
MidazolamDrug
Study participants will receive single dose of IV Midazolam at pre-specified time points.
DiazepamDrug
Study participants will receive single dose of Nasal Diazepam by inhalation at pre-specified time points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 minutes of study intervention administration of Staccato alprazolam in Group 1Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 1
- Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 minutes of study intervention administration of iv midazolam in Group 1Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Up0127 1001
Glendale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.